Bristol Myers Squibb - dokumenter https://www.mynewsdesk.com/no/bristol-myers_squibb/documents Mynewsdesk nyhetsstrøm direkte fra kilden Bristol Myers Squibb - dokumenter https://www.mynewsdesk.com/no/bristol-myers_squibb/documents https://www.mynewsdesk.com/assets/graphics/logos/logo-small-3b24ab90.png 128 23 sv 15 Studie med Opdivo (nivolumab) stoppet Wed, 14 Jan 2015 14:08:13 +0100 https://www.mynewsdesk.com/no/bristol-myers_squibb/documents/studie-med-opdivo-nivolumab-stoppet-42143?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document https://www.mynewsdesk.com/no/bristol-myers_squibb/documents/studie-med-opdivo-nivolumab-stoppet-42143?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document Bristol-Myers Squibb Daclatasvir Marketing Authorization Application for Treatment of Chronic Hepatitis C Validated for Accelerated Regulatory Review by the European Medicines Agency Wed, 08 Jan 2014 13:22:29 +0100 https://www.mynewsdesk.com/no/bristol-myers_squibb/documents/daclatasvir-marketing-authorization-application-for-treatment-of-chronic-hepatitis-c-validated-for-accelerated-regulatory-review-by-the-european-32118?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document https://www.mynewsdesk.com/no/bristol-myers_squibb/documents/daclatasvir-marketing-authorization-application-for-treatment-of-chronic-hepatitis-c-validated-for-accelerated-regulatory-review-by-the-european-32118?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document Bristol-Myers Squibb Faktaark: ORENCIA® (abatacept) ved behandling av revmatoid artritt (RA) Wed, 28 Nov 2012 10:22:25 +0100 ORENCIA® er det første biologiske legemiddelet som blir tilgjengelig både som intravenøs infusjon og selvinjiserende, subkutan administrasjon. https://www.mynewsdesk.com/no/bristol-myers_squibb/documents/faktaark-orencia-r-abatacept-ved-behandling-av-revmatoid-artritt-ra-23464?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document https://www.mynewsdesk.com/no/bristol-myers_squibb/documents/faktaark-orencia-r-abatacept-ved-behandling-av-revmatoid-artritt-ra-23464?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document Bristol-Myers Squibb ORENCIA® (abatacept) Demonstrates Comparable Efficacy to Humira® (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents Wed, 13 Jun 2012 08:31:55 +0200 • ORENCIA demonstrated comparable efficacy to Humira based on a non-inferiority endpoint for ACR20 response at 1 year • Kinetics of response for ACR20, 50 and 70, and inhibition of radiographic progression were generally comparable over 12 months • AMPLE is the first head-to-head study in adults with rheumatoid arthritis comparing two biologic drugs each on a background of methotrexate https://www.mynewsdesk.com/no/bristol-myers_squibb/documents/orencia-r-abatacept-demonstrates-comparable-efficacy-to-humira-r-adalimumab-in-patients-with-moderate-to-severe-rheumatoid-arthritis-in-first-20401?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document https://www.mynewsdesk.com/no/bristol-myers_squibb/documents/orencia-r-abatacept-demonstrates-comparable-efficacy-to-humira-r-adalimumab-in-patients-with-moderate-to-severe-rheumatoid-arthritis-in-first-20401?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=document Bristol-Myers Squibb